Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults

First-in-human trial in US for Gan & Lee type 2 diabetes drug

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

Emcure Pharma launches weight loss drug Poviztra in India

Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management

Novo Nordisk files FDA application for once-weekly obesity drug CagriSema

If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab

Zydus receives FDA’s tentative approval for Empagliflozin and Linagliptin tablets

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic